Below are key performance indicators (KPIs) for each of our four focus areas (Access to Health, Employees, Environmental Sustainability, and Ethics & Transparency), as well as links to the performance data tables found throughout this site.
These KPIs serve as baseline measurements for our corporate responsibility activities, are measured globally unless otherwise noted, and cover all of our business units with the exception of joint ventures.
Access to Health
|Research & Development||2012||2013||2014||2015||2016|
|Top 20 global burdens of illness addressed by our products and pipeline2||55%||88%||88%||88%||88%|
|GCP/PV audits by regulatory agencies or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures*||0||-||0||0||-|
|Established significant external licenses and collaborations3||61||40||35||64||57|
|Narrative of compounds provided to product-development partnerships4||Link|
|* Complete response letter received for Sugammadex (MK-8616) in 2013 and complete response letter received for Januvia (sitagliptin; MK-0431) in 2016.|
|Manufacturing & Supply||2012||2013||2014||2015||2016|
|Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5, 6||0.19%||0.11%||0.22%||0.07%||0.01%|
|Number of local and regional manufacturing partnerships to enable access||84||68||104||179||179|
|Number of products available by local and regional partnerships7||34||354||499||1,157||941|
|New product and device registrations8, 9, 10||204||179||176||156||143|
|Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities with their GCP/PV compliance oversight role11||Link|
|Products submitted that have achieved WHO prequalification||10||11||11||11||11|
|Pricing & Commercialization||2012||2013||2014||2015||2016|
|Number of products which are supported with differential pricing12, 13||NA||24||35||35||40|
|Number of low and lower-middle income countries where inter- and/or intra-country pricing has been implemented14||NA||70||114||121||123|
|Investment in patient- and provider-education programs (in millions)||$71.4||$61.3||$52.3||$80.0||$80.2|
|Health care workers trained through major programs and partnerships15||38,000||22,000||137,000||18,669||32,218|
|Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity building (in millions)15||$24||$24||$32||$31||$28|
|People reached through major programs & partnerships (in millions)15||269||302||267||188||293|
|NA: Not available.|
1. Unless otherwise stated, data for Access to Health are reflective of our Human Health business only; information on our company's Animal Health is reported separately.
2. As defined by the Institute for Health Metrics and Evaluation (IHME), which replaces the previously used WHO chart of leading causes of disease, condition or injury.
3. Starting in 2014, this metric no longer includes select early licenses and research collaborations that were included in the metric for previous years.
4. For information on product-development partnerships, visit the Research & Development page.
5. Definition of Recall Classifications: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049070.htm#RecallClassifications.
6. Beginning in 2014, product recalls include data from our Animal Health business.
7. Increase represented in 2015 is due in part by better visibility to global partner information.
8. Data includes new products and new indications.
9. For information on new registrations by region, visit our Clinical Research page.
10. Data for all years have been updated based on a tracking system upgrade that corrected miscounts in prior years.
11. For information on local regulatory agency GCP/PV training requests, visit our Clinical Research page.
12. Differential pricing intended to facilitate access for the at-need population.
13. Products include HIV treatments, vaccines and other patented products.
14. Countries as defined by the World Bank 2013 GNI Classification, including UN-defined Least Developed Countries.
15. Includes investments by the Office of Corporate Responsibility, MSD for Mothers and/or our company's Foundation.
- Access to Reproductive Health
- Animal Health
- Clinical Research
- Community Investment
- Manufacturing & Supply Chain
- MECTIZAN® Donation Program
- Medical Outreach Program (MMOP)
- MSD for Mothers
- Pricing & Commercialization
- Product Registration
- Research & Development
- Patient Assistance Programs
|Diversity & Inclusion||2012||2013||2014||2015||2016|
|Women in executive roles1||31%||31%||31%||34%||31%|
|Women on the Board||17%||17%||17%||21%||23%|
|Members of underrepresented ethnic groups on the Board||25%||25%||25%||21%||23%|
|Members of underrepresented ethnic groups in executive roles (U.S.)||17%||20%||20%||20%||23%|
|Members of underrepresented ethnic groups in the workforce (U.S.)||24%||24%||24%||26%||26%|
|Response rate to the Voice Survey||77%||77%||78%||NA||85%|
|Employees who completed a health assessment (U.S.)||58%||62%||57%||58%||57%|
|Lost-time incident rate (LTIR)||0.27||0.28||0.20||0.21||0.13|
|Recordable injury rate (RIR)||0.62||0.61||0.57||0.47||0.35|
|Employees who took release time according to the global policy on employee volunteerism2||NA||NA||NA||9%||21%|
|Total recorded volunteer hours3||NA||NA||109,932||80,585||214,862|
|NA: Not available.|
1. “Executive” is defined as the chief executive officer and two structural levels below.
2. Figures involve some estimate where specific data was not available.
3. 2016 figures are based on employee self-recorded volunteer hours and volunteer hours communicated directly to the Office of Corporate Responsibility for certain countries. 2015 marked the first year in which volunteer-hour reporting was based solely on employee self-reporting. Prior years included estimates for unrecorded volunteer hours.
|Greenhouse gas emissions (Scope 1 & 2) (MT CO2e)2||1,856,000||1,760,000||1,630,700||1,501,000||1,409,600|
|Water usage (billion gallons)||8.6||7.5||7.1||6.3||5.5|
|Operational waste generated (MT)||109,470||96,256||83,733||69,856||72,599|
|1. Includes facilities worldwide.|
2. In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired or sold. Adjustments also reflect changes in methodology to ensure consistency from year to year.
Ethics & Transparency
|Employees trained on our Code of Conduct||92%||99%||99%||99%||100%|
|Ratio of substantiated allegations to concerns/issues raised||60%||58%||60%||58%||55%|
|Reported concerns regarding privacy practices, breaches of privacy and losses of personal data and devices that were substantiated1||23%||26%||18%||96%||98%|
|1. Privacy concerns include all concerns escalated to our Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with our privacy standards or that involve the loss of, theft of or unauthorized access to personal data.|